The Institute for Myeloma and Bone Cancer Research announces the addition of Zhi-Wei Li, PhD as Principal Scientist for `The Cure Myeloma Project`
Released on: February 3, 2008, 9:40 pm
Press Release Author: Cheryl A. Cross, MPH, The Institute for Myeloma and Bone Cancer Research
Industry: Non Profit
Press Release Summary: Zhi-Wei Li, Ph.D. formerly of The Moffitt Cancer Research Center affiliated with the University of South Florida will lead scientific efforts for the Institute of Myeloma and Bone Cancer Research's most recent research initiative, "The Cure Myeloma Project."
Press Release Body: Los Angeles, CA - The Institute for Myeloma and Bone Cancer Research (IMBCR) is the only independent, non-profit cancer research institute working to find improved treatment and ultimately, a cure for multiple myeloma - a rare hematological cancer (cancer of the blood cells) that reside in the bone marrow. The American Cancer Society predicts that over 60,000 people are currently living with myeloma and over 16,000 new cases are diagnosed each year. Approximately 10,000 people die each year from multiple myeloma. Over the past five years, the Institute for Myeloma and Bone Cancer Research has carried out groundbreaking research in the field of hematologic cancers. Under the medical direction of Dr. James R. Berenson, a veteran physician-scientist who has been leading investigations and research that has created new therapies for myeloma patients. With 25 years experience in the lab and with patients, Dr. Berenson's primary goal has been to create new drug combinations and treatments to improve the quality of life and longevity of patients with myeloma. While the primary focus of the research at the IMBCR is multiple myeloma and the similarities to other cancers such as leukemia and lymphoma, many mechanisms and therapies discovered in the IMBCR laboratory apply to the treatment of other well-known cancers, particularly cancers that metastasize, or, spread to the bone such as, breast, prostate and lung cancers. 2008 marks the inauguration of The Cure Myeloma Project, a multi-year scientific research initiative that looks at genetic markers of myeloma and how proteins move when targeted. Says Berenson, "The Cure Myeloma Project was created with the hopes of bringing new therapies to existing myeloma patients. Our motto at the IMBCR is "Fast-Tracking a Cure" and I feel that with the addition of Dr. Li who brings a wealth of scientific advancements in the field of multiple myeloma, we will make great strides that will benefit patients and eventually cure this disease."
Dr. Berenson continues, "Dr. Li comes to the IMBCR with tremendous experience, including research specific to in-vivo models for myeloma. He has over ten years working with IKK/NF-kappa B signal transduction, a plasma cell that is key to myeloma and several years researching lymphocyte immunology. Dr. Li is an obvious choice to lead The Cure Myeloma Project because of his extensive work in the field of multiple myeloma, and other life-threatening cancers, such as leukemia and lymphoma." Dr. Zhi-Wei Li, received his Ph.D. in Molecular Biology at the University of Zurich, Switzerland and was a postdoctorate fellow at the University of California, San Diego with funding from the Cancer Research Institute. He holds a M.S. degree in Molecular Biology from the Chinese Academy of Sciences in Beijing, China. He most recently was an Assistant Professor of Research at the Moffitt Cancer Center and Research Institute affiliated with the University of South Florida. Dr. Li has published extensively and has received numerous awards, including research grants from the Multiple Myeloma Research Foundation, The American Cancer Society and the Department of Interdisciplinary Oncology at the Moffitt Cancer Center and Research Institute. He is an Active Member with the American Association for Cancer Research and the American Association for the Advancement of Science. He joins the Institute of Myeloma and Bone Cancer Research as Principal Scientist on "The Cure Myeloma Project". About the Cure Myeloma Project: A multi-year initiative set forth by the research team and board of directors of The Institute for Myeloma and Bone Cancer Research in Los Angeles, California. Initial funding for the project has been provided by the Crane Foundation, the Nancy and Stephen Grand Philanthropic Fund, and the Kramer Family Foundation and members of the IMBCR Board of Directors. The IMBCR is seeking new grants and donations to fund newly initiated biologic and molecular research dedicated solely to, "The Cure Myeloma Project." About Dr. Berenson: Dr. James R. Berenson serves as a member of the National Institute of Health - Center for Scientific Review, Clinical Oncology Study Section. He is a member of the Scientific Boards of the Multiple Myeloma Research Foundation and the International Myeloma Foundation. He serves on both the Foundation and the Scientific Boards of the Leukemia, Lymphoma and Myeloma Society. Dr. Berenson received his undergraduate degree in Science with Distinction from Stanford University and his Doctorate in medicine from the University of California at San Diego (UCSD). Dr. Berenson completed his internship and residency in internal medicine at the University of Utah Medical Center and fellowships in hematology/oncology at the University of California, Los Angeles (UCLA) Dr. Berenson has dual board certifications in Internal Medicine and Medical Oncology. For a full bio: www.berensononcology.com About the IMBCR: The Institute for Myeloma and Bone Cancer Research is a non-profit cancer research organization located in Los Angeles, California. CEO and President, Dr. James R. Berenson created this institute in 2004 out of the belief that a dedicated, stand-alone organization will speed up the advancement of scientific research, devise revolutionary treatments and eventually find a cure for myeloma, bone cancer and other forms of hematologic cancers such as leukemia and lymphoma. The IMBCR is under the executive direction of Geoffrey Gee, Esq., and a board of directors that includes, Ron Rogers, President of Rogers & Company in Los Angeles, California, Richard Brooke Brewer, CEO of Arca Discovery in Denver, Colorado, James A. Tamkin, M.D., F.A.C.P., F.A.C.E., associate clinical professor of medicine at UCLA, George "Geo" Hartley, Esq., an independent attorney and theatrical producer in Washington, D.C., Jill Howell-Kramer of the Kramer Family Foundation in San Francisco, California and Michael F. Richman, M.D., F.A.C.S., F.C.C.P., President and Head of Surgery for The Center for Cholesterol Management and Elite Laser Vein Centers of Los Angeles, California. More information can be found at www.imbcr.org
#### Media Contact: Cheryl A. Cross, MPH 310-406-1035 or 866-900-1035 firstname.lastname@example.org
Web Site: http://www.imbcr.org
Contact Details: Cheryl A. Cross, MPH The Institute for Myeloma and Bone Cancer Research 9201 Sunset Blvd., Suite 300 Los Angeles, CA 90069 310-406-1035 or 866-900-1035 email@example.com